Senate Report Criticizes Gilead’s Pricing Strategy for Sovaldi

Gilead Sciences Inc.'s pricing and marketing strategy for the hepatitis C drug Sovaldi was designed to maximize revenue with little concern for access or affordability, according to a report released Dec. 1 by Sens. Ron Wyden (D-Ore.) and Charles E. Grassley (R-Iowa).

Wyden, the ranking member of the Senate Finance Committee, and Grassley, a senior member of the panel, released the results of an investigation into the pricing and marketing of Sovaldi and its second-wave successor, Harvoni. The investigation found the company pursued a marketing strategy and final wholesale price of Sovaldi—$1,000 per pill, or $84,000 for a single course ...